Advertisement
ACET vs VIR
Which Stock Would AI Choose? Adicet Bio (ACET) vs. Vir Biotechnology (VIR) Stock Comparison
Key Takeaways
- ACET (Adicet Bio) is a clinical-stage cell therapy developer that recently reported positive Phase 1 lupus data, yet its shares remain highly volatile.
- VIR (Vir Biotechnology) swung to a quarterly profit on a major collaboration payment and carries a near-term pivotal hepatitis delta readout.
- The two companies occupy different therapeutic niches: ACET focuses on "off-the-shelf" gamma delta T cell therapies, while VIR spans infectious disease and oncology.
- VIR has a substantially larger cash position and revenue base, while ACET relies on a much smaller market capitalization and a tighter cash runway.
- Both stocks are catalyst-driven, meaning clinical data and regulatory milestones, rather than current earnings, tend to dominate price action.
- Analyst sentiment is broadly constructive on both names, but the risk profiles and timelines differ meaningfully.
Introduction
Investors comparing ACET and VIR are weighing two clinical-stage biotechnology companies with very different pipelines and financial profiles. This stock comparison is most relevant for traders and investors who track catalyst-driven biotech names, where a single data readout or regulatory decision can reshape the entire thesis. Adicet Bio is advancing a cell therapy platform aimed primarily at autoimmune diseases, while Vir Biotechnology is pursuing treatments for chronic hepatitis delta and a portfolio of oncology candidates. Understanding how these companies differ in business model, momentum, and risk can help clarify their relative market positioning.
ACET Overview and Recent Performance
ACET (Adicet Bio) develops allogeneic, or "off-the-shelf," gamma delta T cell therapies engineered with chimeric antigen receptors (CARs) for autoimmune diseases and cancer. Its lead candidate, prula-cel (formerly ADI-001), targets CD20 and is being studied in systemic lupus erythematosus (SLE, a chronic autoimmune disease) with or without lupus nephritis (LN, kidney inflammation caused by lupus).
In recent weeks, the company reported updated Phase 1 data showing durable responses in lupus patients, including complete renal responses in lupus nephritis and remission rates in SLE, with many patients able to discontinue immunosuppressive medications. Several analysts responded by raising price targets and reiterating Buy ratings. Despite the generally positive clinical signal, the shares have experienced notable volatility, with a sharp pullback following the readout even as analyst price targets moved higher. This divergence reflects the inherent uncertainty of early-stage data, ongoing cash-burn considerations, and the small-cap nature of the stock. Adicet reported cash and short-term investments of about $118 million as of mid-2026 and expects that balance to fund operations into the second half of 2027.
VIR Overview and Recent Performance
VIR (Vir Biotechnology) is a clinical-stage biopharmaceutical company focused on serious infectious diseases and cancer. Its lead program is a combination regimen for chronic hepatitis delta, the most severe form of viral hepatitis, with a pivotal Phase 3 trial readout (ECLIPSE-1) expected in the fourth quarter. In oncology, it is advancing PRO-XTEN "dual-masked" T-cell engagers (TCEs), therapies designed to direct immune cells against tumors, including a prostate cancer program partnered with Astellas.
Recent market activity has been shaped by a corporate shift toward profitability. In its most recent quarter, Vir reported roughly $239 million in revenue and a swing to net income, driven largely by an upfront payment tied to the Astellas collaboration. The shares have posted strong year-to-date gains, though they still trade well below prior highs. Vir's balance sheet is a key differentiator, with cash, equivalents, and investments of roughly $809 million as of early 2026, which management expects to fund operations into the second half of 2028. The near-term investment narrative centers on the ECLIPSE-1 hepatitis delta readout and the broader oncology pipeline.
Trending AI Robots
For traders seeking a data-driven way to navigate catalyst-heavy names like ACET and VIR, Tickeron's Trending AI Robots page offers a curated view of its platform. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only the strongest and most suitable performers for current market conditions earn a place in the Trending AI Robots section. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the sets of tickers they trade, so investors can filter by the approach that matches their own objectives. Reviewing the curated list can help traders identify which automated strategies are currently aligned with prevailing market conditions. Explore the Trending AI Robots section to see which bots are leading right now.
Head-to-Head Comparison
At a business-model level, ACET and VIR represent two distinct approaches to biotech value creation. Adicet is a concentrated, single-platform story: its near-term thesis rests largely on prula-cel in lupus, with a solid-tumor candidate and an in vivo CAR-T platform earlier in development. Vir, by contrast, operates across two therapeutic areas, giving it multiple shots on goal but also a wider R&D (research and development) spend.
Financially, the contrast is stark. Vir reported meaningful quarterly revenue and a profit, while Adicet remains pre-revenue with a smaller cash balance. On market capitalization, Vir is the larger company, while Adicet trades as a micro-cap, which can amplify percentage swings. In terms of momentum, Vir has posted stronger year-to-date relative performance, whereas ACET has been choppier around its data events.
Risk profiles also differ. ACET faces binary clinical and financing risk, while VIR's key near-term risk is concentrated in the ECLIPSE-1 hepatitis delta readout and oncology execution. Sector exposure overlaps in biotechnology, but the catalysts and timelines are unrelated, making the two names more complementary than directly competitive.
Tickeron AI Verdict
Based on observable factors such as trend consistency, financial stability, and near-term catalysts, Tickeron's AI would likely lean toward VIR at present. Vir's stronger relative performance, larger cash reserve, recent swing to profitability, and a clearly defined pivotal readout give it a more stable trend profile and clearer catalyst path. ACET offers a potentially higher-reward clinical story, but its smaller capitalization, tighter runway, and post-data volatility suggest a less consistent trend. This assessment is probabilistic and reflects current market conditions rather than a definitive prediction, as both names remain highly sensitive to upcoming clinical and regulatory developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACET is a Hold and VIR is a Hold.
ACET sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for ACET moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACET declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ACET entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Moving Average Convergence Divergence (MACD) for ACET just turned positive on November 04, 2026. Looking at past instances where ACET's MACD turned positive, the stock continued to rise in 39 of 43 cases over the following month. The odds of a continued upward trend are 90%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.242) is normal, around the industry mean (2.904). P/E Ratio (-0.298) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. ACET’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACET’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
VIR in upward trend: price rose above 50-day moving average on October 26, 2026
VIR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend. In 36 of 39 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on VIR as a result. In 77 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for VIR just turned positive on October 27, 2026. Looking at past instances where VIR's MACD turned positive, the stock continued to rise in 33 of 41 cases over the following month. The odds of a continued upward trend are 80%.
The 10-day moving average for VIR crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +7.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 205 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
VIR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 125 of 159 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 51 cases where VIR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.027) is normal, around the industry mean (2.904). P/E Ratio (-6.650) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ACET | VIR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 6 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 45 Fair valued | 20 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 96 | |
PRICE GROWTH RATING 1..100 | 95 | 37 | |
P/E GROWTH RATING 1..100 | 9 | 79 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VIR's Valuation (20) in the null industry is in the same range as ACET (45) in the Medical Distributors industry. This means that VIR’s stock grew similarly to ACET’s over the last 12 months.
VIR's Profit vs Risk Rating (100) in the null industry is in the same range as ACET (100) in the Medical Distributors industry. This means that VIR’s stock grew similarly to ACET’s over the last 12 months.
VIR's SMR Rating (96) in the null industry is in the same range as ACET (98) in the Medical Distributors industry. This means that VIR’s stock grew similarly to ACET’s over the last 12 months.
VIR's Price Growth Rating (37) in the null industry is somewhat better than the same rating for ACET (95) in the Medical Distributors industry. This means that VIR’s stock grew somewhat faster than ACET’s over the last 12 months.
ACET's P/E Growth Rating (9) in the Medical Distributors industry is significantly better than the same rating for VIR (79) in the null industry. This means that ACET’s stock grew significantly faster than VIR’s over the last 12 months.
| ACET | VIR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 82% | N/A |
| Stochastic ODDS (%) | N/A | 2 days ago 82% |
| Momentum ODDS (%) | N/A | 2 days ago 84% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 80% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 78% |
| Advances ODDS (%) | N/A | 2 days ago 76% |
| Declines ODDS (%) | 2 days ago 88% | 4 days ago 81% |
| BollingerBands ODDS (%) | N/A | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 79% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACET’s FA Score shows that 1 FA rating(s) are green while VIR’s FA Score has 1 green FA rating(s).
- ACET’s FA Score: 1 green, 4 red.
- VIR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACET’s TA Score shows that 2 TA indicator(s) are bullish while VIR’s TA Score has 7 bullish TA indicator(s).
- ACET’s TA Score: 2 bullish, 3 bearish.
- VIR’s TA Score: 7 bullish, 2 bearish.
Price Growth
ACET (@Biotechnology) experienced а -18.64% price change this week, while VIR (@Biotechnology) price change was -1.34% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.74%. For the same industry, the average monthly price growth was -13.34%, and the average quarterly price growth was -20.29%.
Reported Earning Dates
ACET is expected to report earnings on Mar 17, 2027.
VIR is expected to report earnings on Feb 25, 2027.
Industries' Descriptions
@Biotechnology (-7.74% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ACET and
Correlation & Price change
A.I.dvisor indicates that over the last year, ACET has been loosely correlated with VIR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ACET jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To ACET | 1D Price Change % | ||
|---|---|---|---|---|
| ACET | 100% | -2.21% | ||
| VIR - ACET | 44% Loosely correlated | +4.90% | ||
| OGI - ACET | 41% Loosely correlated | +5.37% | ||
| RXRX - ACET | 40% Loosely correlated | +5.43% | ||
| COYA - ACET | 38% Loosely correlated | -0.96% | ||
| IMTX - ACET | 38% Loosely correlated | -2.33% | ||
More | ||||
VIR and
Correlation & Price change
A.I.dvisor indicates that over the last year, VIR has been loosely correlated with BEAM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To VIR | 1D Price Change % | ||
|---|---|---|---|---|
| VIR | 100% | +4.90% | ||
| BEAM - VIR | 55% Loosely correlated | +5.55% | ||
| EDIT - VIR | 54% Loosely correlated | +4.62% | ||
| DNLI - VIR | 53% Loosely correlated | +7.76% | ||
| PRME - VIR | 53% Loosely correlated | +9.23% | ||
| RCUS - VIR | 51% Loosely correlated | +2.12% | ||
More | ||||